When is localized prostate cancer clinically insignificant?

Posted on December 21, 2010 by Sitemaster

Among prostate cancer specialists, there has been a broad acceptance — for some time — of the idea that a localized prostate cancer “index” tumor with a Gleason score of 6 or less and a volume of ≤ 0.5 cm3 could be considered to be clinically insignificant and therefore did not (necessarily) need to be treated.

Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: , , , , , | Leave a Comment »

The relevance of clinical stage in diagnosis of localized prostate cancer today

Posted on August 4, 2010 by Sitemaster

The staging systems used by clinicians and pathologists for assignment of the stage of prostate cancer were all developed more than 20 years ago, and have seen only relatively minor adjustments since the introduction of the PSA test.

Filed under: Diagnosis, Management, Risk | Tagged: , , , , | 2 Comments »

Is subclassification of stage T2 disease still relevant?

Posted on October 25, 2009 by Sitemaster

There are three pathological subclassifications of prostate cancer that is confined to the prostate: T2a disease (cancer confined to one half of either the left or right lobe or side of the prostate), T2b disease (cancer that is found throughout one lobe or side of the prostate) and T2c disease (cancer that is evident in [...]

Filed under: Management | Tagged: | 1 Comment »

PSMA protein targeting agent and metastatic disease

Posted on June 17, 2009 by Sitemaster

According to a company press release, Molecular Insight Pharmaceuticals, Inc. presented clinical data earlier today on a development-stage, radiolabeled, small-molecule, molecular imaging pharmaceutical with potential in the diagnosis, staging, and perhaps even the treatment of advanced forms of prostate cancer.

Filed under: Diagnosis, Management, Risk, Treatment | Tagged: , , , , , | 6 Comments »

β-Arrestin 2: yet another possible marker

Posted on May 20, 2009 by Sitemaster

Another report from the Medical College of Georgia identifies a protein called β-arrestin 2 (or βarrestin2) as having lower levels in certain types of prostate cancer cells than in normal prostate cells, while expression of testosterone-stimulated androgen receptors is higher.

Filed under: Diagnosis, Management, Risk | Tagged: , , , , | Leave a Comment »

The Thursday prostate cancer news: February 12, 2009

Posted on February 12, 2009 by Sitemaster

Four new reports today deal with: Higher grade disease in men diagnosed with prostate cancer because of LUTS The role of MR/MRI in prostate biopsy for carefully defined patients Risk for understaging of prostate cancer Sorenafib in treatment of patients with castration-resistant prostate cancer

Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: , , , , , , | Leave a Comment »

Thursday’s news update: November 20, 2008

Posted on November 20, 2008 by Sitemaster

We have separately addressed a report from Australia on the potential of PSA “signatures” as prognostic indicators of prostate cancer progression. In other news today:

Filed under: Diagnosis, Management | Tagged: , , , , | Leave a Comment »

Weekend prostate cancer news update: Saturday, July 26

Posted on July 26, 2008 by Sitemaster

Articles summarized in this weekend news update include information about: The value of endorectal MRI imaging in staging patients with respect to whether they have cancer confined to the prostate or extracapsular disease Patterns of disease recurrence after salvage radical prostatectomy for patients with radiation-recurrent disease The potential of PSA kinetics to improve prediction of likelihood for [...]

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , , , , | Leave a Comment »

Follow

Get every new post delivered to your Inbox.

Join 269 other followers